Bartronics India Ltd. (BIL), a listed technology and services company, has announced a strategic investment of up to INR 50 crore in Hyderabad-based molecular diagnostics innovator Huwel Life Sciences to deliver affordable diagnostics for India and global health markets.

Under the MoU, BIL will acquire a 15 percent equity stake in Huwel, with an option to increase its equity stake by an additional 15 percent.   

The partnership combines Bartronics India’s expertise in scaling businesses with Huwel’s proven innovation capabilities to strengthen India’s healthcare ecosystem, accelerate disease elimination programmes, and establish global leadership in affordable diagnostics.  

BIL will take charge of driving market growth, delivering technology support, managing digital outreach, and developing customized applications, portals, and digital platforms. It will also take the lead in identifying prospective opportunities, initiating engagements, negotiating commercial terms, and securing government, institutional, and international orders — while ensuring that all activities are structured to safeguard and enhance the long-term value interests of both partners.

Huwel has developed over 100 validated diagnostic products across TB, infectious diseases, antimicrobial resistance, viral threats, genetic disorders, and cancer. Its flagship product, QuantiPlus TB Fast Detection Kit, is the only ICMR-approved open-system, affordable RT-PCR solution for TB confirmatory testing in India.

Beyond TB, Huwel’s innovations span pandemic preparedness and emerging viral threats. During COVID-19, it delivered RT-PCR solutions at scale and has since developed diagnostic tools for Nipah and Chandipura viruses.

Speaking on the partnership, Vidhya Sagar Reddy, Managing Director of Bartronics India, said, "It is about building a monopoly-strength product portfolio from India for the world. It also strengthens our role in national health programmes while creating recurring revenue opportunities. We are really proud to be supporting the government's mission to eliminate TB.”

Dr. Rachana Tripathi, CEO of Huwel Life Sciences, commented, "From COVID-19 to Nipah and Chandipura, Huwel has consistently delivered diagnostic innovations that safeguard public health. With our ICMR-certified TB solution and expanding product portfolio—and with BIL’s partnership, we are ready to scale across India and globally."

Looking ahead, BIL and Huwel aim to expand internationally, particularly in Africa and Southeast Asia, positioning India as a global hub for affordable life sciences innovation and manufacturing.